Baseline patient demographics for TETRIS: a prospective, noninterventional study to characterize the use of triple therapy for COPD in Germany
Therapeutic Advances in Respiratory Disease · 2024
DOI: 10.1177/17534666241287621 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2024. Verfasst von Claus F Vogelmeier und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Pulmonary and Critical Care Medicine, University of Marburg, German Center for Lung Research (DZL), Marburg, Germany. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Bronchodilator Agents, Drug Therapy, Combination. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GSK.
Themen: COPD
Abstract (Originalsprache)
Background
Evidence on how decisions regarding escalation to triple therapy and de- or re-escalation are taken and the rationale on which these decisions are based is currently limited in Germany.
Objectives
The TETRIS study aims to elucidate influences on treatment decisions surrounding triple therapy in a real-world practice setting in Germany.
Design
TETRIS is an ongoing, multicenter, prospective, observational cohort study recruiting patients with chronic obstructive pulmonary disease (COPD) with or without asthma who have already been treated with triple therapy for 2–48 weeks.
Methods
For better representation of the treatment reality in Germany, patients are recruited from general practitioners and pulmonologists. Data are collected in two parts. Part 1 involves cross-sectional phenotyping of patients at enrollment. Part 2 involves a 2-year longitudinal follow-up period to monitor/document all visits by the patients during the 24-month observation period per routine clinical practice. Here, we report the demographic and baseline characteristics of 1213 eligible patients recruited to part 1 of the study.
Results
The mean patient age was 66.4 years overall, and 29.3% (356/1213) of patients had no comorbidities. The mean CAT score was 19.4; the number of exacerbations and hospitalizations due to exacerbations in the past 3 years before starting triple therapy was 0.6 and 0.1, respectively. Dual bronchodilation with a long-acting muscarinic antagonist (LAMA) plus a long-acting β-2 agonist (LABA) was the most common therapy for COPD before initiation of triple therapy in 58.3% of patients.
Conclusion
In this real-world setting in Germany, patients with COPD have a relatively low reported exacerbation rate but high symptom burden, and over 70% are multimorbid. Triple therapy is initiated in patients who are primarily highly symptomatic despite being on LAMA + LABA. Future prospective studies in patients with multimorbidity are warranted to better understand the treatment landscape across the disease spectrum. Trial registration: https://clinicaltrials.gov/study/NCT04657211
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Pulmonary and Critical Care Medicine, University of Marburg, German Center for Lung Research (DZL), Marburg, Germany.
- Insaf Respiratory Research Institute, GmbH, Taunusstein, Germany.
- Group Practice and Centre for Allergy, Respiratory and Sleep Medicine, Red Cross Maingau Hospital, Frankfurt am Main, Germany.
- GSK, Brentford, Middlesex, UK.
- Goethe University Frankfurt, University Hospital, Medical Clinic I, Department of Respiratory Medicine, Frankfurt/Main, Germany.
- Velocity Clinical Research Grosshansdorf, formerly Pulmonary Research Institute at LungenClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany.
ORCID-Profile: Kai-Michael Beeh, Jing Claussen
Förderung
- GSK
Zitieren
APA
Vogelmeier, C. F., Beeh, K. M., Kardos, P., Paulsson, T., Rohde, G., Watz, H., Compton, C., Mohan, T., & Claussen, J. (2024). Baseline patient demographics for TETRIS: a prospective, noninterventional study to characterize the use of triple therapy for COPD in Germany. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666241287621
Vancouver
Vogelmeier CF, Beeh KM, Kardos P, Paulsson T, Rohde G, Watz H, et al. Baseline patient demographics for TETRIS: a prospective, noninterventional study to characterize the use of triple therapy for COPD in Germany. Therapeutic Advances in Respiratory Disease. 2024. doi:10.1177/17534666241287621
BibTeX
@article{Vogelmeier2024,
author = {Vogelmeier, Claus F and Beeh, Kai-Michael and Kardos, Peter and Paulsson, Thomas and Rohde, Gernot and Watz, Henrik and Compton, Chris and Mohan, Tharishini and Claussen, Jing},
title = {Baseline patient demographics for TETRIS: a prospective, noninterventional study to characterize the use of triple therapy for COPD in Germany},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2024},
doi = {10.1177/17534666241287621}
}
EUVIMED